Lorus says small molecule series, interleukin-17E show anticancer activity

By Elaine Rigoli

Tampa, Fla., April 3 - Lorus Therapeutics, Inc. released data showing novel anticancer activity from two lead preclinical programs, and the company will present this data at the 97th annual meeting of the American Association for Cancer Research being held in Washington, D.C. this week.

The presentation titled, "Novel series of small molecules suppress in-vitro and in-vivo tumor cell growth of colon carcinoma cells through the induction of Kruppel-like factor 4 (KLF 4)," was presented Monday.

A second presentation titled, "IL-17E, a proinflammatory cytokine, has a novel antitumor function in-vivo," will also be presented.

Lorus, located in Toronto, Ont., is a biopharmaceutical company focused on the research and development of cancer therapies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.